# Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine

> **NCT04818515** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 26 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Atogepant
- **DRUG:** Ubrogepant

## Key facts

- **NCT ID:** NCT04818515
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-17
- **Primary completion:** 2021-06-18
- **Final completion:** 2021-06-18
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2022-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04818515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04818515, "Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04818515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*